Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Phase 2 Study of Canakinumab in Kawasaki Disease
2019-002783-27Phase 2Terminated
- Sponsor
- Amsterdam University Medical Center
- Start
- Aug 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of canakinumab in Kawasaki disease (KD), sponsored by Amsterdam University Medical Center. Primary endpoint: Fever resolution. Started Aug 2019; status: terminated.
02
Drugs
canakinumab
03
Conditions
Kawasaki disease (KD)
Beyond the preview
Go deeper on 2019-002783-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002783-27.